New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate
This article was originally published in The Pink Sheet
Executive Summary
Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.
You may also be interested in...
Capsugel Flexes Breadth Of Capabilities In Development Collaborations
Amit Patel, president of Capsugel’s Dosage Form Solutions business unit, says the firm is able to work more closely with customers in the product development process since it is no longer a subsidiary of Pfizer. Capsugel announced the launch of its Lipidex integrated technology platform June 5.
Capsugel CEO Driesen Plots Post-Pfizer Course
Guido Driesen, president and CEO of Capsugel, says the oral dosage technology firm is having a record year after being divested by Pfizer. In an interview, he discusses the firm’s applications for OTC drugs and nutritionals, as well as Capsugel’s international expansion.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.